000144990 001__ 144990
000144990 005__ 20250717155812.0
000144990 0247_ $$2doi$$a10.1016/j.jocn.2019.12.030
000144990 0247_ $$2pmid$$apmid:31992513
000144990 0247_ $$2ISSN$$a0967-5868
000144990 0247_ $$2ISSN$$a1532-2653
000144990 0247_ $$2altmetric$$aaltmetric:74720777
000144990 037__ $$aDZNE-2020-00354
000144990 041__ $$aEnglish
000144990 082__ $$a610
000144990 1001_ $$aHerm, Juliane$$b0
000144990 245__ $$aImpact of atrial fibrillation burden on cognitive function after left atrial ablation - Results of the MACPAF study.
000144990 260__ $$aBurlington, Mass.$$bHarcourt$$c2020
000144990 264_1 $$2Crossref$$3print$$bElsevier BV$$c2020-03-01
000144990 3367_ $$2DRIVER$$aarticle
000144990 3367_ $$2DataCite$$aOutput Types/Journal article
000144990 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1752760475_26599
000144990 3367_ $$2BibTeX$$aARTICLE
000144990 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144990 3367_ $$00$$2EndNote$$aJournal Article
000144990 520__ $$aAtrial fibrillation (AF) is associated with cognitive decline and dementia irrespective of AF-related ischemic stroke. We investigated whether AF burden after ablation in patients with symptomatic paroxysmal AF has an impact on cognitive function. After enrolment to the prospective MACPAF study, study patients received an insertable loop recorder (ILR) and underwent serial neurological/cognitive assessment. To compare cognitive function, the delta of baseline and six months test results (Δpre/post) and a score to assess overall cognitive performance were computed. Thirty patients (median age 65 years (IQR 57-69), 40% female) were divided into groups according to median AF burden (<0.5% vs. ≥0.5%) after ablation. Overall cognitive performance did not differ in patients with an AF burden < 0.5% (median 120% [IQR 100-150]) vs. ≥0.5% (median 120% [IQR 100-160]) within six months after ablation (p = 0.74). Comparing Δpre/post, patients with an AF burden ≥ 0.5% showed significantly better results in the digit-span backwards test (median + 1 [IQR 0 - +2 points]) compared to patients with an AF burden < 0.5% (median 0 [IQR -1-+1]) six months after ablation (p = 0.03). In patients with an AF burden < 0.5%, there was a statistical trend towards better results in the RAVLT test (median + 3 [IQR 0-+4]; p = 0.08) and the ROC test (median + 3 [IQR -1-+5; p = 0.07) compared to patients with an AF burden ≥ 0.5% (median -1 [IQR -3-+2] words and median -1 [IQR -5-+2] points, respectively). Therefore, AF burden had no significant impact on cognitive performance within six months after ablation. Clinical Trial Registration: clinicaltrials.gov NCT01061931.
000144990 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000144990 542__ $$2Crossref$$i2020-03-01$$uhttps://www.elsevier.com/tdm/userlicense/1.0/
000144990 588__ $$aDataset connected to CrossRef, PubMed,
000144990 650_2 $$2MeSH$$aAged
000144990 650_2 $$2MeSH$$aAtrial Fibrillation: complications
000144990 650_2 $$2MeSH$$aAtrial Fibrillation: physiopathology
000144990 650_2 $$2MeSH$$aAtrial Fibrillation: surgery
000144990 650_2 $$2MeSH$$aCatheter Ablation: methods
000144990 650_2 $$2MeSH$$aCognition
000144990 650_2 $$2MeSH$$aCognition Disorders: epidemiology
000144990 650_2 $$2MeSH$$aCognition Disorders: etiology
000144990 650_2 $$2MeSH$$aFemale
000144990 650_2 $$2MeSH$$aHumans
000144990 650_2 $$2MeSH$$aMale
000144990 650_2 $$2MeSH$$aMiddle Aged
000144990 650_2 $$2MeSH$$aProspective Studies
000144990 650_2 $$2MeSH$$aTreatment Outcome
000144990 7001_ $$aSchirdewan, Alexander$$b1
000144990 7001_ $$aKoch, Lydia$$b2
000144990 7001_ $$aWutzler, Alexander$$b3
000144990 7001_ $$aFiebach, Jochen B$$b4
000144990 7001_ $$0P:(DE-2719)2811033$$aEndres, Matthias$$b5$$udzne
000144990 7001_ $$aKopp, Ute A$$b6
000144990 7001_ $$0P:(DE-HGF)0$$aHaeusler, Karl Georg$$b7$$eCorresponding author
000144990 77318 $$2Crossref$$3journal-article$$a10.1016/j.jocn.2019.12.030$$b : Elsevier BV, 2020-03-01$$p168-172$$tJournal of Clinical Neuroscience$$v73$$x0967-5868$$y2020
000144990 773__ $$0PERI:(DE-600)2009190-4$$a10.1016/j.jocn.2019.12.030$$gVol. 73, p. 168 - 172$$p168-172$$tJournal of clinical neuroscience$$v73$$x0967-5868$$y2020
000144990 8564_ $$uhttps://pub.dzne.de/record/144990/files/DZNE-2020-00354_Restricted.pdf
000144990 8564_ $$uhttps://pub.dzne.de/record/144990/files/DZNE-2020-00354_Restricted.pdf?subformat=pdfa$$xpdfa
000144990 909CO $$ooai:pub.dzne.de:144990$$pVDB
000144990 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811033$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000144990 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000144990 9141_ $$y2020
000144990 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-10
000144990 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-17$$wger
000144990 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-17
000144990 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-17
000144990 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-17
000144990 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN NEUROSCI : 2021$$d2022-11-17
000144990 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-17
000144990 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-17
000144990 9201_ $$0I:(DE-2719)1811005$$kAG Endres$$lInterdisciplinary Dementia Research$$x0
000144990 980__ $$ajournal
000144990 980__ $$aVDB
000144990 980__ $$aI:(DE-2719)1811005
000144990 980__ $$aUNRESTRICTED